Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Novel concept of the border niche: glioblastoma cells use oligodendrocytes progenitor cells (GAOs) and microglia to acquire stem cell-like features.

Hide T, Shibahara I, Kumabe T.

Brain Tumor Pathol. 2019 Apr;36(2):63-73. doi: 10.1007/s10014-019-00341-2. Epub 2019 Apr 9. Review.

PMID:
30968276
2.

Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border.

Hide T, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu JI, Mukasa A, Yano S.

EBioMedicine. 2018 Apr;30:94-104. doi: 10.1016/j.ebiom.2018.02.024. Epub 2018 Mar 1.

3.

Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.

Mukherjee S, Fried A, Hussaini R, White R, Baidoo J, Yalamanchi S, Banerjee P.

J Exp Clin Cancer Res. 2018 Jul 25;37(1):168. doi: 10.1186/s13046-018-0792-5.

4.

Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.

de Vrij J, Maas SL, Kwappenberg KM, Schnoor R, Kleijn A, Dekker L, Luider TM, de Witte LD, Litjens M, van Strien ME, Hol EM, Kroonen J, Robe PA, Lamfers ML, Schilham MW, Broekman ML.

Int J Cancer. 2015 Oct 1;137(7):1630-42. doi: 10.1002/ijc.29521. Epub 2015 Apr 7.

5.

Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.

Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J.

Neuro Oncol. 2016 Apr;18(4):507-17. doi: 10.1093/neuonc/nov171. Epub 2015 Aug 27.

6.
7.

EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment.

Yin Y, Qiu S, Li X, Huang B, Xu Y, Peng Y.

J Neuroinflammation. 2017 Nov 13;14(1):220. doi: 10.1186/s12974-017-0993-4.

8.

Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain.

van der Vos KE, Abels ER, Zhang X, Lai C, Carrizosa E, Oakley D, Prabhakar S, Mardini O, Crommentuijn MH, Skog J, Krichevsky AM, Stemmer-Rachamimov A, Mempel TR, El Khoury J, Hickman SE, Breakefield XO.

Neuro Oncol. 2016 Jan;18(1):58-69. doi: 10.1093/neuonc/nov244. Epub 2015 Oct 3.

9.

Exploiting Microglial Functions for the Treatment of Glioblastoma.

Dello Russo C, Lisi L, Tentori L, Navarra P, Graziani G, Combs CK.

Curr Cancer Drug Targets. 2017;17(3):267-281. doi: 10.2174/1568009616666160813191240. Review.

PMID:
27528361
10.

Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.

Dahan P, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D, Lubrano V, Toulas C, Cohen-Jonathan Moyal E, Lemarie A.

Cell Death Dis. 2014 Nov 27;5:e1543. doi: 10.1038/cddis.2014.509.

11.

Developmental stage of oligodendrocytes determines their response to activated microglia in vitro.

Miller BA, Crum JM, Tovar CA, Ferguson AR, Bresnahan JC, Beattie MS.

J Neuroinflammation. 2007 Nov 26;4:28.

12.

Liposomal TriCurin, A Synergistic Combination of Curcumin, Epicatechin Gallate and Resveratrol, Repolarizes Tumor-Associated Microglia/Macrophages, and Eliminates Glioblastoma (GBM) and GBM Stem Cells.

Mukherjee S, Baidoo JNE, Sampat S, Mancuso A, David L, Cohen LS, Zhou S, Banerjee P.

Molecules. 2018 Jan 18;23(1). pii: E201. doi: 10.3390/molecules23010201.

13.

PNIPAAm-co-Jeffamine® (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells.

Heffernan JM, McNamara JB, Borwege S, Vernon BL, Sanai N, Mehta S, Sirianni RW.

Biomaterials. 2017 Oct;143:149-158. doi: 10.1016/j.biomaterials.2017.05.007. Epub 2017 May 6.

14.

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M.

Oncotarget. 2013 Sep;4(9):1527-46.

15.

Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis.

Feng X, Szulzewsky F, Yerevanian A, Chen Z, Heinzmann D, Rasmussen RD, Alvarez-Garcia V, Kim Y, Wang B, Tamagno I, Zhou H, Li X, Kettenmann H, Ransohoff RM, Hambardzumyan D.

Oncotarget. 2015 Jun 20;6(17):15077-94.

16.

Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas.

Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ.

PLoS One. 2012;7(8):e43339. doi: 10.1371/journal.pone.0043339. Epub 2012 Aug 22.

17.

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.

Hutter G, Theruvath J, Graef CM, Zhang M, Schoen MK, Manz EM, Bennett ML, Olson A, Azad TD, Sinha R, Chan C, Assad Kahn S, Gholamin S, Wilson C, Grant G, He J, Weissman IL, Mitra SS, Cheshier SH.

Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006. doi: 10.1073/pnas.1721434116. Epub 2019 Jan 2.

18.

SERPINA3 induced by astroglia/microglia co-culture facilitates glioblastoma stem-like cell invasion.

Li Y, Dong X, Cai J, Yin S, Sun Y, Yang D, Jiang C.

Oncol Lett. 2018 Jan;15(1):285-291. doi: 10.3892/ol.2017.7275. Epub 2017 Oct 26.

19.

MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties.

Lin JC, Tsai JT, Chao TY, Ma HI, Chien CS, Liu WH.

Radiother Oncol. 2018 Nov;129(2):352-363. doi: 10.1016/j.radonc.2018.09.014. Epub 2018 Oct 12.

PMID:
30322656
20.

Glioblastoma: Defining Tumor Niches.

Hambardzumyan D, Bergers G.

Trends Cancer. 2015 Dec;1(4):252-265.

Supplemental Content

Support Center